Claris Lifesciences is currently trading at Rs. 353.20, down by 10.80 points or 2.97% from its previous closing of Rs. 364.00 on the BSE.
The scrip opened at Rs. 361.10 and has touched a high and low of Rs. 364.90 and Rs. 345.10 respectively. So far 462810 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 430.10 on 16-Dec-2016 and a 52 week low of Rs. 217.30 on 14-Sep-2016.
Last one week high and low of the scrip stood at Rs. 369.50 and Rs. 357.00 respectively. The current market cap of the company is Rs. 1921.88 crore.
The promoters holding in the company stood at 50.13%, while institutions and non-institutions held 28.08% and 21.79% respectively.
Claris Lifesciences has reportedly received 18 observations from US Food and Drug Administration (USFDA) for its Ahmedabad plant. This was inspected between July 27 and August 4, 2017. The Ahmedabad site is an Ex-Claris injectable site as the company sold its injectable business to Baxter for $625 million.
Claris Lifesciences is engaged in manufacturing of drugs and pharmaceutical products. The Company manufactures and markets products across multiple delivery systems, markets and therapeutic segments, including anesthesia and analgesics, blood products, anti-invective's, critical care, and nephrology.
| Company Name | CMP |
|---|---|
| Redington | 228.90 |
| Adani Enterprises | 2231.00 |
| Amrapali Industries | 17.40 |
| Rashi Peripheral | 475.00 |
| PDS | 297.35 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: